<?xml version="1.0" encoding="UTF-8"?>
<ref id="pone.0200849.ref019">
 <label>19</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Ison</surname>
   <given-names>MG</given-names>
  </name>, 
  <name>
   <surname>de Jong</surname>
   <given-names>MD</given-names>
  </name>, 
  <name>
   <surname>Gilligan</surname>
   <given-names>KJ</given-names>
  </name>, 
  <name>
   <surname>Higgs</surname>
   <given-names>ES</given-names>
  </name>, 
  <name>
   <surname>Pavia</surname>
   <given-names>AT</given-names>
  </name>, 
  <name>
   <surname>Pierson</surname>
   <given-names>J</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>End points for testing influenza antiviral treatments for patients at high risk of severe and life-threatening disease</article-title>. 
  <source>The Journal of infectious diseases</source>. 
  <year>2010</year>;
  <volume>201</volume>(
  <issue>11</issue>):
  <fpage>1654</fpage>â€“
  <lpage>62</lpage>. 
  <pub-id pub-id-type="doi">10.1086/652498</pub-id>
  <?supplied-pmid 20423224?>
  <pub-id pub-id-type="pmid">20423224</pub-id>
 </mixed-citation>
</ref>
